Literature DB >> 7964903

Blood-brain barrier abnormalities in longstanding multiple sclerosis lesions. An immunohistochemical study.

E E Kwon1, J W Prineas.   

Abstract

Thirty-five randomly selected plaques from five patients with longstanding multiple sclerosis were examined immunohistochemically for evidence of extravascular serum proteins. One lesion showed histological evidence of active demyelination and 34 were inactive. In the one active lesion and in 26 of the 34 inactive lesions, serum proteins were detected outside blood vessels in a distribution consistent with leakage during life. The findings suggest that the blood-brain barrier (BBB) is permanently damaged in many old plaques, although to a degree not often detectable by current gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA)-enhanced magnetic resonance imaging (MRI). The findings also suggest that in patients with multiple sclerosis, a breached BBB is not by itself sufficient to induce active demyelination. Continuous exposure of demyelinated axons and glia to cytokines, antibody or other factors present in the circulation might be important, however, in preventing oligodendrocyte regeneration and new myelin formation in longstanding lesions.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7964903     DOI: 10.1097/00005072-199411000-00010

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  47 in total

1.  Enhancing patterns in multiple sclerosis: evolution and persistence.

Authors:  J He; R I Grossman; Y Ge; L J Mannon
Journal:  AJNR Am J Neuroradiol       Date:  2001-04       Impact factor: 3.825

Review 2.  Mast cells and inflammation.

Authors:  Theoharis C Theoharides; Konstantinos-Dionysios Alysandratos; Asimenia Angelidou; Danae-Anastasia Delivanis; Nikolaos Sismanopoulos; Bodi Zhang; Shahrzad Asadi; Magdalini Vasiadi; Zuyi Weng; Alexandra Miniati; Dimitrios Kalogeromitros
Journal:  Biochim Biophys Acta       Date:  2010-12-23

3.  Characterizing contrast-enhancing and re-enhancing lesions in multiple sclerosis.

Authors:  Z Campbell; D Sahm; K Donohue; J Jamison; M Davis; C Pellicano; S Auh; J Ohayon; J A Frank; N Richert; F Bagnato
Journal:  Neurology       Date:  2012-04-25       Impact factor: 9.910

Review 4.  Cytokine-induced inflammation in the central nervous system revisited.

Authors:  J A Martiney; C Cuff; M Litwak; J Berman; C F Brosnan
Journal:  Neurochem Res       Date:  1998-03       Impact factor: 3.996

5.  Thrombin mutant W215A/E217A treatment improves neurological outcome and attenuates central nervous system damage in experimental autoimmune encephalomyelitis.

Authors:  Norah G Verbout; Xiaolin Yu; Laura D Healy; Kevin G Phillips; Erik I Tucker; András Gruber; Owen J T McCarty; Halina Offner
Journal:  Metab Brain Dis       Date:  2014-05-09       Impact factor: 3.584

6.  Insulin-like growth factor I treatment reduces demyelination and up-regulates gene expression of myelin-related proteins in experimental autoimmune encephalomyelitis.

Authors:  D L Yao; X Liu; L D Hudson; H D Webster
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-20       Impact factor: 11.205

7.  Endothelial cell integrin laminin receptor expression in multiple sclerosis lesions.

Authors:  R A Sobel; J R Hinojoza; A Maeda; M Chen
Journal:  Am J Pathol       Date:  1998-08       Impact factor: 4.307

8.  Elevated fibrinogen levels in neuromyelitis optica is associated with severity of disease.

Authors:  Ya Zhang; Xiaomei Zhang; Dongsheng Liu; Honghao Wang; Suyue Pan; Dongmei Wang; Xiong Chen
Journal:  Neurol Sci       Date:  2016-07-23       Impact factor: 3.307

Review 9.  New concepts on progressive multiple sclerosis.

Authors:  Hans Lassmann
Journal:  Curr Neurol Neurosci Rep       Date:  2007-05       Impact factor: 5.081

Review 10.  Theiler's virus infection: a model for multiple sclerosis.

Authors:  Emilia L Oleszak; J Robert Chang; Herman Friedman; Christos D Katsetos; Chris D Platsoucas
Journal:  Clin Microbiol Rev       Date:  2004-01       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.